Dendreon Corp fka DNDNQ

[steveporsche]

"If the welfare of cancer patients were the main issue, wouldn’t you want DNDN to wait for another 56 events (360-204) in order to give the trial the best possible chance to succeed?

From a patient-advocacy standpoint, surely the delay in obtaining 56 more events pales in comparison to the nightmare scenario where: a) Provenge really does have good efficacy; b) the new 9902b trial fails; and c) the old 9902b trial would have succeeded."

You describe my nightmare - I wish they would have left the trial alone and waited for those hopefully 56 high HR events. Obtaining financing certainly those not seem to be a problem for them. Waiting another 6 to 12 months would not have been such a big deal since the trial has already been going on for nearly 5 years.